• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

简化合并症指数预测低强度预处理异基因造血细胞移植中的非复发死亡率。

The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation.

机构信息

Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Department of Bone Marrow Transplantation and Cancer Immunotherapy, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.

出版信息

Br J Haematol. 2023 Dec;203(5):840-851. doi: 10.1111/bjh.19055. Epub 2023 Aug 24.

DOI:10.1111/bjh.19055
PMID:37614192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10843799/
Abstract

Comorbidity assessment before allogeneic haematopoietic cell transplantation (allo-HCT) is essential for estimating non-relapse mortality (NRM) risk. We previously developed the Simplified Comorbidity Index (SCI), which captures a small number of 'high-yield' comorbidities and older age. The SCI was predictive of NRM in myeloablative CD34-selected allo-HCT. Here, we evaluated the SCI in a single-centre cohort of 327 patients receiving reduced-intensity conditioning followed by unmanipulated allografts from HLA-matched donors. Among the SCI factors, age above 60, mild renal impairment, moderate pulmonary disease and cardiac disease were most frequent. SCI scores ranged from 0 to 8, with 39%, 20%, 20% and 21% having scores of 0-1, 2, 3 and ≥4 respectively. Corresponding cumulative incidences of 3-year NRM were 11%, 16%, 22% and 27%; p = 0.03. In multivariable models, higher SCI scores were associated with incremental risks of all-cause mortality and NRM. The SCI had an area under the receiver operating characteristic curve of 65.9%, 64.1% and 62.9% for predicting 1-, 2- and 3-year NRM versus 58.4%, 60.4% and 59.3% with the haematopoietic cell transplantation comorbidity index. These results demonstrate for the first time that the SCI is predictive of NRM in patients receiving allo-HCT from HLA-matched donors after reduced-intensity conditioning.

摘要

在进行异基因造血细胞移植(allo-HCT)之前,对合并症进行评估对于估计非复发死亡率(NRM)风险至关重要。我们之前开发了简化合并症指数(SCI),该指数可捕获少数“高产量”合并症和年龄较大。在清髓性 CD34 选择 allo-HCT 中,SCI 可预测 NRM。在这里,我们在接受强度降低的条件预处理后接受 HLA 匹配供体未处理同种异体移植物的 327 例患者的单中心队列中评估了 SCI。在 SCI 因素中,年龄超过 60 岁,轻度肾功能不全,中度肺部疾病和心脏病最为常见。SCI 评分范围为 0 至 8,分别有 39%,20%,20%和 21%的评分分别为 0-1,2,3 和≥4。相应的 3 年 NRM 的累积发生率分别为 11%,16%,22%和 27%;p=0.03。在多变量模型中,较高的 SCI 评分与全因死亡率和 NRM 的增量风险相关。与移植后血液学并发症指数相比,SCI 预测 1 年,2 年和 3 年 NRM 的受试者工作特征曲线下面积分别为 65.9%,64.1%和 62.9%,为 58.4%,60.4%和 59.3%。这些结果首次表明,SCI 可预测接受强度降低条件预处理后接受 HLA 匹配供体 allo-HCT 的患者的 NRM。

相似文献

1
The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation.简化合并症指数预测低强度预处理异基因造血细胞移植中的非复发死亡率。
Br J Haematol. 2023 Dec;203(5):840-851. doi: 10.1111/bjh.19055. Epub 2023 Aug 24.
2
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT.简化合并症指数:预测异基因造血干细胞移植后非复发死亡率的新工具。
Blood Adv. 2022 Mar 8;6(5):1525-1535. doi: 10.1182/bloodadvances.2021004319.
3
CD34 Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .CD34 细胞选择与减低强度预处理和非清髓移植在年龄 >50 岁的急性髓系白血病和骨髓增生异常综合征患者中的异基因造血细胞移植。
Biol Blood Marrow Transplant. 2018 May;24(5):964-972. doi: 10.1016/j.bbmt.2017.12.804. Epub 2018 Jan 2.
4
Pretransplant serum FT3 levels in recipients predict early non-relapse mortality after myeloablative allogeneic haematopoietic cell transplantation from matched sibling donors.接受者移植前的血清游离三碘甲状腺原氨酸(FT3)水平可预测来自匹配同胞供者的清髓性异基因造血细胞移植后的早期非复发死亡率。
Hematology. 2018 Jan;23(1):38-43. doi: 10.1080/10245332.2017.1345098. Epub 2017 Jun 26.
5
Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.不同强度预处理方案对经典型霍奇金淋巴瘤患者异基因造血干细胞移植结局的影响。
Br J Haematol. 2020 Aug;190(4):573-582. doi: 10.1111/bjh.16664. Epub 2020 Apr 21.
6
Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.比较两种移植前预测模型和使用不同截断点的灵活 HCT-CI,以确定低、中、高危组:在接受 allo-RIC 的患者人群中,灵活 HCT-CI 是 NRM 和 OS 的最佳预测因子。
Biol Blood Marrow Transplant. 2010 Mar;16(3):413-20. doi: 10.1016/j.bbmt.2009.11.008. Epub 2009 Nov 14.
7
Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.haplo 移植后使用环磷酰胺的异基因干细胞移植合并症指数的影响。
Cancer Med. 2021 Oct;10(20):7194-7202. doi: 10.1002/cam4.4262. Epub 2021 Sep 21.
8
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.非清髓性异基因造血干细胞移植中造血细胞移植特异性合并症指数的验证。
Biol Blood Marrow Transplant. 2017 Oct;23(10):1744-1748. doi: 10.1016/j.bbmt.2017.06.005. Epub 2017 Jun 28.
9
Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.联合造血细胞移植合并症指数和欧洲血液与骨髓移植组评分可更好地对接受低强度异基因造血细胞移植的高危患者进行分层。
Biol Blood Marrow Transplant. 2014 Jan;20(1):66-72. doi: 10.1016/j.bbmt.2013.10.011. Epub 2013 Oct 17.
10
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.造血细胞移植合并症指数(HCT-CI)可预测淋巴瘤和骨髓瘤患者在接受减低强度或非清髓性异基因干细胞移植后的临床结局。
Leukemia. 2009 Jun;23(6):1131-8. doi: 10.1038/leu.2009.1. Epub 2009 Feb 5.

引用本文的文献

1
Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation.1102 例异基因造血干细胞移植患者合并症对结局的影响。
Bone Marrow Transplant. 2024 Nov;59(11):1525-1533. doi: 10.1038/s41409-024-02395-z. Epub 2024 Aug 13.
2
Nephrons and non-relapse mortality: simplified comorbidity index and acute kidney injury are associated with NRM in adults undergoing allogeneic hematopoietic cell transplant.肾单位与非复发死亡率:简化合并症指数和急性肾损伤与接受异基因造血细胞移植的成人患者的非复发死亡率相关。
Front Transplant. 2024 Mar 18;3:1352413. doi: 10.3389/frtra.2024.1352413. eCollection 2024.
3

本文引用的文献

1
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.移植后环磷酰胺为基础的移植物抗宿主病预防。
N Engl J Med. 2023 Jun 22;388(25):2338-2348. doi: 10.1056/NEJMoa2215943.
2
The use of prognostic models in allogeneic transplants: a perspective guide for clinicians and investigators.预测模型在异基因移植中的应用:临床医生和研究人员的视角指南。
Blood. 2023 May 4;141(18):2173-2186. doi: 10.1182/blood.2022017999.
3
Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study.
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML.
是否有用?一种针对 TP53 突变性 MDS/AML 的异基因造血细胞移植的当代方法。
Blood Adv. 2024 Feb 13;8(3):553-561. doi: 10.1182/bloodadvances.2023010417.
4
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation.各部分之和:我们能从同种异体移植的共病评分中学到什么以及学不到什么。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):715-722. doi: 10.1182/hematology.2023000458.
低强度预处理方案治疗的急性髓系白血病移植受者的合并症:ALWP-EBMT 研究。
Blood Adv. 2023 May 23;7(10):2143-2152. doi: 10.1182/bloodadvances.2022008656.
4
Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis.二十年来异基因干细胞移植治疗复发/难治性急性髓系白血病的纵向结局:ALWP/EBMT 分析。
Clin Cancer Res. 2022 Oct 3;28(19):4258-4266. doi: 10.1158/1078-0432.CCR-22-0809.
5
Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT.既往合并症与异基因造血细胞移植结局的关联。来自欧洲血液与骨髓移植协会(EBMT)的一项回顾性分析。
Bone Marrow Transplant. 2022 Feb;57(2):183-190. doi: 10.1038/s41409-021-01502-8. Epub 2021 Oct 30.
6
Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation Is a Good Choice for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis of Randomized Controlled Trials.减低强度预处理后行异基因造血干细胞移植是急性髓系白血病和骨髓增生异常综合征的良好选择:一项随机对照试验的荟萃分析
Front Oncol. 2021 Oct 7;11:708727. doi: 10.3389/fonc.2021.708727. eCollection 2021.
7
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT.简化合并症指数:预测异基因造血干细胞移植后非复发死亡率的新工具。
Blood Adv. 2022 Mar 8;6(5):1525-1535. doi: 10.1182/bloodadvances.2021004319.
8
Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.移植前肾功能不全对异基因造血细胞移植后结局的影响。
Transplant Cell Ther. 2021 May;27(5):410-422. doi: 10.1016/j.jtct.2021.02.030. Epub 2021 Feb 26.
9
Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria.根据美国国立卫生研究院的共识标准,建立慢性移植物抗宿主病数据的标准化审查和裁决系统。
Adv Cell Gene Ther. 2019 Oct;2(4). doi: 10.1002/acg2.62. Epub 2019 May 2.
10
Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.来自HLA匹配供者和替代供者的异基因造血干细胞移植的结局:欧洲血液与骨髓移植学会登记处的回顾性分析
Lancet Haematol. 2019 Nov;6(11):e573-e584. doi: 10.1016/S2352-3026(19)30158-9. Epub 2019 Aug 30.